Tilray’s Lyphe Bet Isn’t About Europe — It’s About Being Ready When Washington Moves
Tilray's Lyphe acquisition signals a deliberate commercial build for U.S. cannabis rescheduling — and most competitors are structurally unprepared...
cannabis rescheduling